View Older Stories
-
Increasing unusual option volume: ZSL AVTR RVMD OPTT TAL URNM
-
Avantor (AVTR) 36K contracts of January 9 puts trade
-
Increasing unusual option volume: AVTR CCCC DAWN VTGN TWO RYAM ULCC ETR
-
Jefferies Downgrades Avantor Inc. (AVTR) to Underperform
-
BofA Securities Downgrades Avantor Inc. (AVTR) to Neutral
-
Nephron Downgrades Avantor Inc. (AVTR) to Sell
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Increasing unusual option volume: AVTR JBS SLG ELAN
-
Raymond James Downgrades Avantor Inc. (AVTR) to Market Perform
-
Avantor launches sterile sampling platform and PUPSIT assemblies
-
Barclays Downgrades Avantor Inc. (AVTR) to Equalweight
-
JPMorgan Downgrades Avantor Inc. (AVTR) to Neutral
-
Avantor Inc. (AVTR) PT Lowered to $14 at BofA Securities
-
Avantor (AVTR) 53K contracts of November 10 puts trade, share price down 21%
-
Increasing unusual option volume: AVTR GTES PLNT UTHR NOK FI LRN ERIC WU BBWI
-
Avantor (AVTR) Misses Q3 EPS by 1c, Misses on Revenue
-
Avantor (AVTR) call put ratio 1.9 calls to 1 put as share price down 1.5%
-
Avantor partners with p-Chip to develop digital traceability solutions
-
Avantor partners with BlueWhale Bio to improve CAR-T cell manufacturing
-
Avantor names Gregory Summe as board chairman effective January 2026
-
Avantor responds to Engine Capital letter, names new CEO
-
Engine Capital calls for governance changes at Avantor
-
Avantor Inc. (AVTR) PT Lowered to $17 at RBC Capital as 'Revenue Headwinds Persist'
-
Avantor Inc. (AVTR) PT Lowered to $13 at UBS
-
Avantor Inc. (AVTR) PT Lowered to $12 at Stifel
-
Avantor Inc. (AVTR) PT Lowered to $14 at Raymond James
-
Jefferies Downgrades Avantor Inc. (AVTR) to Hold
-
Avantor (AVTR) Misses Q2 EPS by 1c
-
Wolfe Research Reiterates Peerperform Rating on Avantor Inc. (AVTR)
-
Avantor names Emmanuel Ligner as new CEO effective August 18
-
Evercore Lists Additions to TAP Outperform List of Life Science & Diagnostic Tools Names
-
Avantor on watch on vague chatter
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
KeyBanc on Avantor Inc. (AVTR): 'We See the Potential for Upside'
-
Raymond James Reiterates Outperform Rating on Avantor Inc. (AVTR)
-
Increasing unusual call option volume: AVTR NEXT SHLS IGT ARRY DDD RPD DVA TAN UNH CYTK
-
Goldman Sachs Downgrades Avantor Inc. (AVTR) to Neutral
-
Avantor Inc. (AVTR) PT Lowered to $15 at Bernstein SocGen Group
-
Avantor Inc. (AVTR) PT Lowered to $20 at RBC Capital
-
TD Cowen Downgrades Avantor Inc. (AVTR) to Hold
-
Morgan Stanley Downgrades Avantor Inc. (AVTR) to Equalweight
-
Stifel Downgrades Avantor Inc. (AVTR) to Hold
-
Avantor (AVTR) Reports In-Line Q1 EPS
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
TD Cowen Issues Stock Conclusions Following Bioproduction Market Survey
-
Avantor Inc. (AVTR) PT Lowered to $31 at RBC Capital Amid 'Lower Growth'
-
Avantor Inc. (AVTR) PT Lowered to $22 at Bernstein SocGen Group
-
Avantor Inc. (AVTR) PT Lowered to $26 at Stifel
-
Avantor (AVTR) spreader of March 19 and 20 puts
-
Avantor (AVTR) Tops Q4 EPS by 1c

